Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Medtronic (NYSE: MDT) today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.

A Delaware judge correctly interpreted transcatheter aortic valve-replacement device patents that were asserted against ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Emboline, Inc., a leading innovator in full-body embolic protection devices for transcatheter procedures, today announced completion of patient enrollment in its Protect the Head to Head (ProtectH2H) ...

Saint Alphonsus in Boise earned a three-star TAVR ranking from STS and ACC, placing it among the nation’s top heart programs ...

Facing an upcoming surgical procedure often brings stress and anxiety, but not for Della de Corse. When she learned she would ...

Do all heart valve replacements need open-heart surgery? Let's know the new techniques that could change everything ...

Edwards Lifesciences Corp (EW) has reached a new 52-week high, with its stock price climbing to 83.02 USD. According to InvestingPro data, the company maintains strong financial health with a "GOOD" ...